This article is mentioned in:

Introduction

Esophageal cancer is one of the most aggressive cancers in the world. According to the latest epidemiological data, in 2018, the number of incidences of esophageal cancer and the number of death from esophageal cancer were reported to be 572,034 and 508,585 worldwide, respectively, which makes it the ninth and sixth highest rates for incidence and mortality among all the malignant tumors (1). Therefore, there is an immediate need to find more effective methods to diagnose, treat, and predict the prognosis of esophageal cancer.

Yes-associated protein (YAP), a candidate oncogene located on chromosome 11q22, is a negative regulator of the Hippo pathway, which has been previously reported as a tumor suppressor pathway in Drosophila and mammals (2,3). Previous studies suggest that the Hippo-Yap pathway plays an important role in the genesis and progression of tumors (4,5). Increased YAP expression has been associated with the progression of several human cancers, including cervical cancer (6), pancreatic ductal adenocarcinoma (7) and human urothelial carcinoma of the bladder (8). In addition, YAP overexpression is associated with poor prognosis in human urothelial carcinoma of the bladder (8), ovarian cancer (9), and colorectal cancer (10). Our previous studies have shown that YAP overexpression plays vital roles in the progression and metastasis of prostate and pancreatic cancer (11,12). However, a previous study has reported that the overexpression of YAP was associated with poor overall survival (OS) in esophageal cancer in Japan (13). Further research is required to understand the role of the expression level of YAP in esophageal cancer and its importance in prognosis prediction.

Epithelial-mesenchymal transition (EMT) is a process described as the transition of cells from epithelial phenotype to mesenchymal phenotype and during this process cells gain more migratory and invasive properties (14). Although YAP has previously been reported to be associated with tumor metastasis via EMT in several tumors, including non-small cell lung cancer (15), breast cancer (16), pancreatic ductal adenocarcinoma (17), and hepatocellular carcinoma (18), its involvement in ESCC still remains unclear. There are no reports, so far, with regard to YAP regulation of tumor migration and invasion through EMT in ESCC.

Since one previous study reported that downregulation of YAP inhibits proliferation and induces apoptosis in ESCC cells (19), the exact role of YAP in ESCC remains largely unclear. The present study aimed to investigate the role of YAP expression in tissue samples from patients with ESCC by performing a stratified analysis based on pathological TNM stage to provide further insights into the influence of YAP expression for prognosis of patients with ESCC, with respect to both OS and disease-free survival (DFS). Furthermore, small interfering RNA (siRNA) was transfected into Eca109 and Kyse150 cells and the effects of YAP inhibition on these ESCC cells was investigated to explore the underlying molecular mechanism.

Materials and methods

Patients and samples

A total of 107 paraffin-embedded tumor tissue samples from patients who underwent esophagectomy at Qilu Hospital of Shandong University (Jinan, China) were collected between January 2008 and October 2008. All cases were confirmed as ESCC by three people as stated in the immunohistochemical (IHC) analysis section. Samples were excluded from the study as follows: i) If the patient received radiation therapy or chemotherapy before surgery; ii) if the patient died or was untraceable during follow-up and iii) if the patient was diagnosed with more than one primary tumor. The clinicopathological data, including age, sex, history of smoking and alcohol consumption, differentiation degree, invasion depth (T stage), lymph node metastasis (N stage), pathological TNM (pTNM) (20), and adjuvant treatment after surgery were obtained from the clinical or pathological records. The present study was approved by The Ethics Committee of Qilu Hospital. All patients in the study were anonymous and provided written informed consent.

Follow-up

In the first 2 years after surgery, patients were contacted by telephone every 3 months to enquire about their recovery and assess the level of recurrence, if any. More detailed instructions were provided according to tumor progression if recurrence occurred. After 2 years, information regarding the patients was collected every 6 months until November 2013, unless they were either untraceable or had died.

IHC analysis

Tumor tissues of patients with ESCC were fixed in 10% formalin for 12 h at 4°C and embedded in paraffin. The paraffin-embedded tissues were cut into 5 µm thick sections, and IHC staining was performed using the Streptavidin-BiotinComplex kit according to the manufacturer's protocol (cat. no. SA1022; Wuhan Boster Biological Technology Co., Ltd.). Tissue sections were mounted on to the microslides and incubated for 1 h at 60°C before de-waxing in xylene and hydrated in graded concentrations of alcohol (95, 90, 85, 80 and 75%). Then the sections were placed in a solution of sodium citrate (pH 6.0) and were heated to 93°C, and maintained at 90°C for 15 min to retrieve the antigen. The solution was cooled to room temperature and 3% H2O2 was subsequently added at room temperature for 10 min, to block the non-specific protein binding sites and inactivate the endogenous peroxidase. After blocking with 5% BSA (Wuhan Boster Biological Technology Co., Ltd.) for 20 min at room temperature, the sections were incubated overnight at 4°C with mouse polyclonal primary antibody against YAP (dilution 1:300; cat. no. 4912; Cell Signaling Technology, Inc.). Then, the sections were incubated with biotinylated goat anti-rabbit antibody from the kit for 20 min at 37°C. Finally, the slides were counterstained with hematoxylin at 25°C for 2 min dehydrated in graded alcohol solution (75, 80, 85, 90, 95 and 100%) and xylene, and covered with coverslips using neutral balsam.

The IHC images were scored for positive staining intensity in five high-power fields using a light microscope (magnification, ×400) independently by three people, including a pathologist and two authors of the current study who did not participate in the IHC staining (LZ and YJ). The intensity score was graded as follows: i) None, 0; ii) mild, 1; iii) moderate, 2; and iv) intense, 3. The percentage of positive tumor cells was assessed according to the following patterns: i) No staining, 0; ii) ≤10%, 1; iii) 10–50%, 2; iv) and >50% 3. The staining intensity was assessed as follows: i) Negative, 0; ii) weak, 1; iii) moderate, 2; and iv) strong, 3. The final score was the combination of the intensity score and the positive percentage score for each section. A score of 1–5 was designated as low expression and an overall score of 6–9 was designated as high expression of YAP in ESCC tissues (21).

Cell culture and transfection

Human esophageal squamous carcinoma cell lines Eca109, TE-10 and TE-11 were obtained from Procell Life Science & Technology Co., Ltd. The Kyse150 cell line was purchased from Cell Bank, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Kyse140 was kindly provided by Professor Xinyuan Guan (Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China). The cells were grown in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.), and supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin antibiotic solution. Human esophageal squamous carcinoma Eca109 cells were cultured in RPMI-1640 supplemented with only 10% FBS. The cells were incubated at 37°C in a humidified incubator containing 5% CO2.

Eca109 and Kyse150 cell lines were transfected with YAP-specific siRNA oligonucleotides synthesized by GenePharma using EndoFectin™ MAX (GeneCopoeia Inc.). YAP-specific siRNA oligonucleotides were synthesized according to the following target sequences: YAP#1, 5′-CAGGTGATACTATCAACCAAA-3′ and YAP#2, 5′-GACCAATAGCTCAGATCCTTT-3′. Non-targeting siRNA (silencer negative control siRNA, siNC, forward: 5′-CCCAUUCAUUGUUGUCACUTT-3′, reverse: 5′-AGUGACAACAAUGAAUGGGTT-3′) was also transfected into Eca109 and Kyse150 cell lines as the negative control. The final concentration of the siRNA used was 50 nM. After transfection for 48 h, the cells were used in the subsequent experiment.

Western blot analysis

After transfection for 48 h, cells were lysed, and proteins were extracted using RIPA (cat. no. P0013C; Beyotime Institute of Biotechnology) and determined by a BCA protein assay. The proteins (25 µg/lane) were separated by SDS-PAGE (5% gel for concentration and 10% gel for separation). Then, the separated proteins were transferred onto polyvinylidene difluoride membranes. The membrane was blocked with 5% skimmed milk in TBST (pH 7.4) at room temperature for 1 h, and incubated with primary antibodies against YAP (dilution 1:1,000), vimentin (dilution 1:1,000; cat. no. 5741; Cell Signaling Technology, Inc.), E-cadherin (dilution 1:1,000; cat. no. ab15148; Abcam), N-cadherin (dilution 1:1,000; cat. no. 22018-1-AP; ProteinTech Group, Inc.) and GAPDH (dilution 1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology, Inc.) overnight at 4°C, then incubated with horseradish peroxidase-conjugated goat anti-rabbit (cat. no. s0001) and goat anti-mouse (cat. no. s0002) immunoglobulin G secondary antibodies (diluted 1:5,000; Affinity Biosciences) for 1 h at 25°C. Immunoreactivity was detected using an enhanced chemiluminescence reaction kit (Pierce, Thermo Fisher Scientific, Inc.) and the bands were quantified by densitometry using ImageJ software (version 1.8.0; National Institutes of Health). GAPDH was used as the loading control.

Transwell migration and invasion assay

ESCC cells were resuspended in serum-free RPMI-1640 medium and added to the upper chamber of Transwell inserts (8-µm pore size, 6.5-mm diameter; Costar; Corning, Inc.) at a density of 3.0×105 cells/ml. The lower chamber contained RPMI-1640 medium with 15% FBS. After incubation for 24 h, a cotton-tipped swab was used to swab the cells on the upper chamber. The migrated cells, which were attached to the lower surface of the membrane, were fixed with pure methanol for 30 min at 25°C and stained with 0.1% crystal violet (Sigma-Alrich; Merck KGaA) for 20 min at 25°C. The numbers of migrated cells were counted (5 fields per filter) using an inverted light microscope at a magnification of ×100 and the mean number was subsequently calculated. The experiments were performed in triplicate and repeated three times. The procedure for the Transwell invasion assay was similar to the migration assay except that the membrane was precoated with Matrigel (Corning, Inc.) and the time of incubation was increased to 36 h.

Statistical analysis

χ2 test was performed to evaluate the association between YAP expression and clinicopathological factors in ESCC. Kaplan-Meier analysis and log-rank test was used to calculate the survival rate and assess the difference between the two subgroups (the YAP overexpression and YAP low expression groups), respectively. Cox regression model was used in univariate and multivariate analyses, to identify significant independent prognostic factors associated with ESCC. For cell experiments, the data are presented as the mean ± standard deviation and three individual experiments were performed in triplicate. One-way analysis of variance followed by Tukey's post hoc test was used to compare the data from different groups. All statistical analyses were performed using SPSS v17.0 software (SPSS, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

Clinicopathological characteristics of patients with ESCC

Clinicopathological characteristics of the 107 patients with ESCC are shown in Table I. Out of the 107 patients, a total of 20 (18.7%) were females and 87 (81.3%) were males, with a median age of 61 years, ranging from 32 to 84 years. A total of 54 (50.5%) patients had a former or current cigarette smoking history and 49 (45.8%) had a history of alcohol consumption. The median follow-up time was 49.50 months (range, 4.40–0.40 months).

Table I. Baseline characteristics of the 107 esophageal squamous cell carcinoma patients.

Table I.

Baseline characteristics of the 107 esophageal squamous cell carcinoma patients.

Characteristics	Value, n (%)
Sex
Female	20 (18.7)
Male	87 (81.3)
Age
Mean ± SD	61.20±9.266
Median, n (range)	61 (32–84)
Smoking
Yes	54 (50.5)
No	53 (49.5)
Drinking
Yes	49 (45.8)
No	58 (54.2)
Differentiation degree
Well	27 (25.2)
Middle	55 (51.4)
Poor	25 (23.4)
T stage
T1	4 (3.7)
T2	42 (39.3)
T3	56 (52.3)
T4	5 (4.7)
N stage
N0	56 (52.3)
N1-3	51 (47.7)
pTNM stage
I	5 (4.7)
III	56 (52.3)
III	46 (43.0)
Follow-up time
Mean ± SD	43.20±22.83
Median, n (range)	49.50
	(4.40–70.40)
YAP expression
Low	65 (60.7)
Over	42 (39.3)
Adjuvant treatment
None	63 (58.9)
Radiotherapy	17 (15.9)
Chemotherapy	9 (8.4)
CRT	18 (16.8)

[i] CRT, radiochemotherapy; T stage, invasion depth; N stage, lymph node metastasis; pTNM, pathological TNM.

YAP expression level in ESCC tissues

YAP expression level in the tumor tissues was investigated using IHC staining and shown in brown. As shown in Fig. 1A and B, YAP was mainly positively expressed in the cytoplasm, but it was also observed in the nucleus. IHC staining showed that YAP was overexpressed in 39.3% (42/107) of the samples and its expression was low in 60.7% (65/107) of the samples.

Figure 1. Immunohistochemical staining of YAP in esophageal squamous cell cancer tissues and Kaplan-Meier analysis and log-rank test of YAP expression for DFS and OS. (A) Overexpression and (B) low expression levels of YAP. YAP expression was localized to the cytoplasm of the cells. Magnification, ×400. (C and D) Kaplan-Meier analysis and log-rank test of YAP for (C) DFS and (D) OS. YAP overexpression significantly predicted decreased DFS (P=0.004) and decreased OS (P<0.001). DFS, disease-free survival; YAP, yes-associated protein; OS, overall survival.

The association of YAP expression with clinicopathological features

To better understand the role of YAP expression level in the progression of ESCC, the data was analyzed using χ2 test. Overexpression of YAP was significantly associated with increased N stage of ESCC (P=0.029). However, there were no significant associations with the other clinicopathological features (P>0.05; Table II).

Table II. Association between clinicopathological features of esophageal squamous cell carcinoma and YAP expression in tumor tissues.

Table II.

Association between clinicopathological features of esophageal squamous cell carcinoma and YAP expression in tumor tissues.

	YAP expression
Clinicopathological features	Low, n=65	Over, n=42	P-valuea
Age
<60	28	22	0.428
≥60	37	20
Sex
Male	51	36	0.449
Female	14	6
Smoking
No	34	19	0.554
Yes	31	23
Drinking
No	35	23	0.926
Yes	30	19
Differentiation
Well	18	9	0.146
Moderate	36	19
Poor	11	14
T stage
T1-2	31	15	0.238
T3-4	34	27
N stage
N0	40	16	0.029b
N1-3	25	26
pTNM
I–II	42	19	0.071
III	23	23
Adjuvant treatment
None	35	28	0.417
Radiotherapy	13	4
Chemotherapy	5	4
CRT	12	6

a χ² test.

b P<0.05. CRT, radiochemotherapy; T stage, invasion depth; N stage, lymph node metastasis; pTNM, pathological TNM.

The prognostic value of YAP expression in ESCC

The mean survival time of all 107 patients was 43.20±22.83 months (range 4.40–70.40 months). Kaplan-Meier analysis was performed along with log-rank test to investigate the relationship between YAP expression and prognosis. Compared to low expression of YAP, its overexpression was significantly associated with decreased DFS (P=0.004) and OS (P<0.001; Fig. 1C and D). Furthermore, the prognostic significance of YAP expression in patient subgroups stratified by pTNM stage (I and II vs. III) was also investigated, and the results revealed significant associations between YAP overexpression and poor survival in patients with late stage ESCC, but not in early stage ESCC (I and II; Fig. 2).

Figure 2. Kaplan-Meier analysis and log-rank test of YAP in subgroups of pTNM stage. (A and B) Kaplan-Meier curves for DFS stratified according to pTNM stage. YAP overexpression was associated with DFS in patients with stage III ESCC (P=0.003), but not associated with stage I and II (P>0.05). (C and D) Kaplan-Meier curves for OS stratified by pTNM stage. YAP overexpression was associated with worse OS in ESCC patients with stage III ESCC (P=0.011), and not in stage I and II (P>0.05). YAP, yes-associated protein; ESCC, esophageal squamous cell cancer; pTNM, pathological TNM.

Univariate and multivariate survival analyses

To further identify the role of YAP expression, univariate and multivariate analyses were performed. Univariate analysis showed that age, N stage, pTNM and YAP expression were statistically significantly associated with OS and DFS (P<0.05). Since previous studies reported that sex, smoking status, alcohol consumption, T stage, differentiation degree, and adjuvant treatment might play critical roles in prognosis of ESCC patients (22,23), all factors were included in the multivariate analysis, and the result indicated YAP overexpression is an independent prognostic factor for OS (HR, 2.727; 95% CI 1.556–4.780; P<0.001) and DFS (HR, 2.161; 95% CI, 1.223–3.818; P=0.008; Table III).

Table III. Univariate and multivariate analysis of prognostic variables for esophageal squamous cell carcinoma.

Table III.

Univariate and multivariate analysis of prognostic variables for esophageal squamous cell carcinoma.

	Overall survival			Disease-free survival
	Univariate analysis	Multivariate analysis	Univariate analysis	Multivariate analysis
Variable	P-value	HR (95% CI)	P-value	P-value	HR (95% CI)	P-value
Sex		1.528			0.699
Male vs. female	0.598	(0.670–3.484)	0.313	0.999	(0.303–1.613)	0.402
Age		0.559			0.941
<60 vs. ≥60	0.030a	(0.318–0.981)	0.043a	0.585	(0.533–1.662)	0.835
Smoking		0.931			0.639
Yes vs. no	0.921	(0.469–1.847)	0.838	0.212	(0.335–1.218)	0.174
Drinking		1.910			0.951
Yes vs. no	0.282	(0.957–3.812)	0.067	0.762	(0.488–1.851)	0.882
T stage		0.872			0.785
T1-2 vs. T3 −4	0.445	(0.466–1.631)	0.668	0.452	(0.422–1.458)	0.443
N stage		1.530			1.035
N0 vs. N1-3	<0.001a	(0.533–4.395)	0.430	0.001a	(0.365–2,937)	0.948
Differentiation		0.783			0.885
Well vs. moderate vs. poor	0.658	(0.526–1.165)	0.227	0.915	(0.595–1.316)	0.545
pTNM		1.805			3.108
I–II vs. III	<0.001a	(0.608–5.357)	0.287	<0.001a	(1.038–9.310)	0.043a
YAP expression		2.727			2.161
Low vs. over	0.001a	(1.556–4.780)	<0.001a	0.005a	(1.223–3.818)	0.008a
CRT		0.974			0.907
None vs. RT vs.	0.785	(0.768–1.237)	0.831	0.620	(0.708–1.163)	0.443
CT vs. RT+CT

a P<0.05. HR, hazard ratio; CI, confidence interval; RT, radiotherapy; CT, chemotherapy; CRT, Radiochemotherapy; T stage, invasion depth; N stage, lymph node metastasis; pTNM, pathological TNM.

Expression analysis of YAP protein in ESCC cell lines

Five common ESCC cell lines (TE-10, TE-11, Kyse150, Kyse140 and Eca109) were used to screen for cell lines with high YAP expression. Since Kyse150 and Eca109 expressed higher levels of YAP than other three cell lines, they were selected for further experiments. The results of the screening by western blot are shown in Fig. S1.

Downregulation of YAP protein expression inhibits the expression of EMT markers in ESCC

To investigate the function of YAP in ESCC, siRNA was used to specifically knockdown YAP expression in ESCC cells. YAP siRNA and siNC were successfully transfected into the cells, and western blot analysis was performed. The analysis showed that YAP expression was successfully downregulated by siYAP but not by siNC, at the protein level (Fig. 3). Western blot analysis was also performed to detect levels of EMT-related proteins. Compared with the control group, levels of vimentin and N-cadherin were significantly reduced when YAP was downregulated, while that of E-cadherin was significantly increased, in both cell lines (Eca109 and Kyse150). Western blotting results showed that YAP could regulate levels of EMT-related proteins in ESCC cells.

Figure 3. YAP is associated with the expression of epithelial-mesenchymal transition markers in esophageal squamous cell cancer cell lines. (A) Representative immunoblots and quantitative analysis of the expression levels of vimentin, N-cadherin, E-cadherin and YAP after siYAP transfection in (B) Eca109 and (C) Kyse150 cells. Data are presented as the mean ± standard error of the mean, and this procedure was performed in triplicate. **P<0.01 vs. control group. YAP, yes-associated protein; si, small interfering; NC, negative control; Con, control.

Downregulation of YAP inhibits cell migration and invasion of ESCC cells

To identify whether YAP affects the ability of cell migration and invasion in Eca109 and Kyse150 cells, transwell migration and invasion assays were performed. Compared with the control group, cell migration and invasion were both significantly decreased by the downregulation of YAP after siYAP#1 and siYAP#2 transfection (P<0.001), in both cell lines. However, no significant difference was found between the control and siNC groups (Fig. 4).

Figure 4. YAP regulates cell migration and invasion in vitro. Cell images of migration for (A) Eca109 and (C) Kyse150 cells and of invasion for (B) Eca109 and (D) Kyse150 cells stained with crystal violet (magnification, ×100). (E-H) The number of migrated and invasive cells in the YAP knockdown group was significantly less compared with those in the control, in both Eca109 and Kyse150 cells. ***P<0.001 vs. control group.

Discussion

The oncogenic role of Hippo-YAP signaling pathway has been reported in various human malignancies (6–9,24). Our previous research revealed that YAP overexpression in prostate and pancreatic cancers promoted tumor progression and metastasis (11,12). However, there are few reports regarding YAP expression in ESCC. In the present study, the level of YAP expression was detected in ESCC tissues and its association with clinicopathological features was analyzed. The analysis showed that YAP expression was only associated with N stage of tumor, however this could be due to the small sample size. Consistent with observations by previous studies, the results also indicate that compared with low expression of YAP, overexpression of YAP predicted poorer OS and DFS (6–9,24). Different statistical methods suggested that YAP expression level could serve as an independent factor for predicting poor prognosis, especially in patients with stage III ESCC, when stratified based on pTNM stage.

The mechanisms underlying YAP-regulated progression and prognosis of ESCC have not been verified. YAP was found to aid esophageal cancer cells develop cancer stem cell-like properties through driving SRY-box 9 expression (21). There is a previous report suggesting that downregulation of YAP inhibits proliferation and induces apoptosis in Eca109 cells (19). Other possible mechanisms of YAP regulation have been reported in other cell lines and tumors. It has been proven that YAP oncoprotein can overcome inhibition caused by high cell-contact and promote cell proliferation in NIH-3T3 cells and MCF10A human breast epithelial cell line (25). YAP overexpression was further confirmed to trigger EMT in MCF10A cells (3). In papillary thyroid cancer B-CPAP and KI cell lines, knockdown of YAP was found to inhibit the proliferation, migration, and invasion, and cause cell cycle arrest and induce autophagy of tumor cells (24). In addition, in prostate cancer, YAP acted as a regulator of cell motility, invasion, castration-resistant growth and hence might be a potential therapeutic target (11). In gastric cancer, it was found that Netrin-1 promotes metastasis of gastric cancer by upregulating YAP expression via its transmembrane receptor neogenin (26). In addition, YAP could regulate the initiation and progression of cervical (6) and ovarian cancer (9) through the ErbB signaling pathway. Previous studies have reported that activated YAP could cause the upregulation of TGF-α, amphiregulin, and epidermal growth factor receptor, facilitating the formation of a positive signaling loop to promote cervical and ovarian cancer cell proliferation (6,9). There are reports regarding the tumor suppressive effect of YAP, either by inhibiting WNT signaling (27) or by triggering DNA damage-induced apoptosis (28). Studies have shown that the YAP signaling pathway was associated with EMT (15–18). Nevertheless, the mechanism of YAP overexpression in ESCC tissues and further influence on the prognosis remain to be elucidated. The present study presents the potential mechanism of YAP regulation in ESCC, possibly through EMT.

There are several limitations in the present study. First, as a retrospective cohort study, the sample number was small, which might have influenced the reliability of the results. Second, there could have been more suitable cutoff values for determining the overexpression and the reduced expression of YAP, which could improve predicting the prognosis. Third, more detailed elucidation of the mechanism of YAP expression affecting the prognosis remains to be discovered. Further studies are required to propose suitable methods to target the elevated expression of YAP and thereby improve the prognosis.

Supplementary Material

Supporting Data

Acknowledgements

The authors would like to thank Dr. Xinyuan Guan (Department of Clinical Oncology Cancer Research Center, University of Hong Kong, Hong Kong, China) for offering us the ESCC cell line.

Funding

The present study was supported by National Natural Science Foundation of China (grant nos. 81773228, 81572958 and 81602007), Natural Science Foundation of Shandong Province (grant no. ZR2016HB68), Nanshan Project of Yantai for Shandong University (grant no. 2014QLKY31) and Key Research and Development Program of Shandong Province (grant no. 2017GSF18153).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' contributions

YQ, LZ, JW and YJ performed the experiments, analysis and wrote the manuscript. PC, CW and WY generated the data and performed the analyses. ZW, QS, BT and YC interpreted the data, drafted the manuscript and made critical revisions. All authors discussed the results and reviewed the manuscript.

Ethics approval and consent to participate

The present study was approved by The Ethics Committee of Qilu Hospital. All the patients in the study were anonymous and provided written informed consent.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References